



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

#23

Food and Drug Administration
Rockville MD 20857

DEC 28 1999

Re: Tasmar®
Docket No. 98-0480
JAN 11 2000
RECEIVED
OFFICE OF THE ASSISTANT
COMMISSIONER FOR PATENTS

The Honorable Q. Todd Dickinson
Deputy Assistant Commissioner for
Patent Policy and Projects
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

Dear Commissioner Dickinson:

This is in regard to the patent term extension application for U.S. Patent No. 5,236,952 filed by Hoffman-La Roche, Inc. under 35 U.S.C. § 156. The patent claims the human drug product Tasmar® (tolcapone), new drug application NDA 20-697.

In the November 27, 1998, issue of the Federal Register (63 Fed. Reg. 65599), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before May 26, 1999, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: George W. Johnston
Hoffmann-La Roche, Inc.
340 Kingsland Street
Nutley, NJ 07110



HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville MD 20857

HPD-7

Official Business

Penalty For Private Use \$300



The Honorable Q. Todd Dickinson
Deputy Assistant Commissioner for Patent
Policy and Projects
Office of the Assistant Commissioner for
Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

